

Andrew J Plodkowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4202025/publications.pdf>

Version: 2024-02-01

53
papers

5,435
citations

257101

24
h-index

197535

49
g-index

55
all docs

55
docs citations

55
times ranked

8202
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
2	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
3	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	0.8	747
4	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , 2016, 17, 1653-1660.	5.1	365
5	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <i>Cancer Immunology Research</i> , 2018, 6, 1093-1099.	1.6	258
6	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
7	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247.	0.5	172
8	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	0.5	151
9	Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. <i>Cancer Discovery</i> , 2018, 8, 686-695.	7.7	149
10	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	3.4	117
11	Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1713-1719.	0.5	84
12	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
13	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2019, 14, 802-815.	0.5	71
14	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35.	1.3	69
15	Dual-Energy CT Angiography for Detection of Pulmonary Emboli: Incremental Benefit of Iodine Maps. <i>Radiology</i> , 2018, 289, 546-553.	3.6	66
16	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2209-2215.	3.2	65
17	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
18	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	0.5	53

#	ARTICLE	IF	CITATIONS
19	Preoperative Computed Tomography Findings Predict Surgical Resectability of Thymoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1023-1030.	0.5	42
20	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	3.2	40
21	Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. <i>Cancer Discovery</i> , 2021, 11, 59-67.	7.7	38
22	Outcomes to first-line pembrolizumab in patients with PD-L1-high (>50%) non-small cell lung cancer and a poor performance status. <i>Journal of Clinical Oncology</i> , 2020, 38, e001007.		36
23	Postoperative complications after thoracic surgery for lung cancer. <i>Clinical Imaging</i> , 2015, 39, 735-749.	0.8	35
24	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. <i>Advances in Radiation Oncology</i> , 2018, 3, 391-398.	0.6	33
25	What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?. <i>Lung Cancer</i> , 2018, 118, 83-89.	0.9	27
26	Pattern and Prognostic Implications of Cardiac Metastases Among Patients With Advanced Systemic Cancer Assessed With Cardiac Magnetic Resonance Imaging. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	25
27	Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (<2 cm) Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 270-276.	0.7	24
28	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	1.3	24
29	From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?. <i>Lung Cancer</i> , 2015, 90, 321-325.	0.9	23
30	Atypical presentation of Legionella pneumonia among patients with underlying cancer: A fifteen-year review. <i>Journal of Infection</i> , 2016, 72, 45-51.	1.7	16
31	Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3797-3803.	3.2	15
32	Radiogenomic evaluation of lung cancer: Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?. <i>Clinical Imaging</i> , 2017, 42, 147-151.	0.8	14
33	Computed tomography-derived assessments of regional muscle volume: Validating their use as predictors of whole body muscle volume in cancer patients. <i>British Journal of Radiology</i> , 2018, 91, 20180451.	1.0	12
34	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	0.6	11
35	Case report of malignant pulmonary parenchymal glomus tumor: imaging features and review of the literature. <i>Clinical Imaging</i> , 2016, 40, 144-147.	0.8	9
36	CT features of HER2-mutant lung adenocarcinomas. <i>Clinical Imaging</i> , 2018, 51, 279-283.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Perfusion defects on dual-energy CTA in patients with suspected pulmonary embolism correlate with right heart strain and lower survival. <i>European Radiology</i> , 2021, 31, 2013-2021.	2.3	9
38	Imaging of Thoracic Cavity Tumors. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 709-733.	0.6	8
39	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1796-1802.	3.2	8
40	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
41	Percutaneous computed tomography guided biopsy of sub-solid pulmonary nodules: differentiating solid from ground glass components at the time of biopsy. <i>Clinical Imaging</i> , 2021, 69, 332-338.	0.8	7
42	Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 42.	1.6	7
43	Diagnostic utility and clinical implication of late gadolinium enhancement cardiac magnetic resonance for detection of catheter associated right atrial thrombus. <i>Clinical Imaging</i> , 2020, 62, 17-22.	0.8	4
44	Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study. <i>Clinical Imaging</i> , 2021, 71, 29-33.	0.8	4
45	Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?. <i>Lung Cancer</i> , 2021, 153, 158-164.	0.9	4
46	Immune checkpoint inhibitor-related pneumonitis: Acute lung injury with rapid progression and organizing pneumonia with less severe clinical disease. <i>Histopathology</i> , 0, , .	1.6	4
47	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	3
48	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <i>Lung Cancer</i> , 2021, 161, 60-67.	0.9	2
49	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e81-e83.	1.1	1
50	Type A thymoma presenting with bone metastasis. <i>Histopathology</i> , 2018, 73, 701-703.	1.6	1
51	Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?. <i>Clinical Imaging</i> , 2021, 69, 133-138.	0.8	1
52	COVID-19 in patients with cancer: can baseline radiologic severity and early evolution predict clinical outcomes?. <i>European Radiology</i> , 2021, , 1.	2.3	0
53	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 11-16.	0.5	0